Drawing for GWPCARE CANNABIDIOL IN RESISTANT EPILEPSY

USPTO serial 86367440

GWPCARE CANNABIDIOL IN RESISTANT EPILEPSY

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
STRUCK, ROBERT J
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with GWPCARE CANNABIDIOL IN RESISTANT EPILEPSY?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Michelle L. Visser

MICHELLE L. VISSER Rader Fishman & Grauer Pllc39533 Woodward Ave Ste 140Bloomfield Hills, MI 48304-5098UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations and substances for the treatment of pain, neuropathic pain, cancer pain, perioperative pain, oncology, cancer symptoms, multiple sclerosis, spasticity, convulsions, seizures, epilepsy, paediatric epilepsy, intractable childhood epilepsy with generalized tonic-clonic seizures (ICE-GTC), generalized epilepsy with febrile seizures plus (GEFS+), dup 15, Doose syndrome, bladder dysfunction, inflammatory bowel disease, ulcerative colitis, Crohn's disease, Alzheimer's, Dravet syndrome, Lennox-Gastaut syndrome (LGS), spinal cord injury, head injury, bone disorders, chromosome disorders, inflammatory disorders, inflammation, arthritis, metabolic disorders, oncology, cancer symptoms, neurodegenerative diseases, diseases of the central nervous system, peripheral neuropathy, neurogenic symptoms, hypoxic-ischemic encephalopathy, stroke, motion sickness, chemically induced sickness, diabetes, obesity, obesity associated with diabetes, bulimia, psychiatric disorders, schizophrenia, and drug, alcohol and nicotine abuse; veterinary preparations and substances for the treatment of pain, neuropathic pain, cancer pain, perioperative pain, oncology, cancer symptoms, spasticity, convulsions, seizures, epilepsy, bladder dysfunction, inflammatory bowel disease, ulcerative colitis, spinal cord injury, head injury, bone disorders, chromosome disorders, inflammatory disorders, inflammation, arthritis, metabolic disorders, oncology, cancer symptoms, neurodegenerative diseases, diseases of the central nervous system, peripheral neuropathy, neurogenic symptoms, Hypoxic-ischemic encephalopathy, stroke, motion sickness and chemically induced sickness, diabetes, obesity, obesity associated with diabetes; herbs for medicinal purposes; medicinal herbs; medicinal oils; medicinal infusions for treating pain, neuropathic pain, cancer pain, perioperative-operative pain, oncology, cancer symptoms, multiple sclerosis, spasticity, convulsions, seizures, epilepsy, paediatric epilepsy, intractable childhood epilepsy with generalized tonic-clonic seizures (ICE-GTC), generalized epilepsy with febrile seizures plus (GEFS+), dup 15, Doose syndrome, bladder disfunction, inflammatory bowel disease, ulcerative colitis, Crohn's disease, Alzheimer's, Dravet syndrome, Lennox-Gastaut syndrome (LGS), spinal cord injury, head injury, bone disorders, chromosome disorders, inflammatory disorders, inflammation, arthritis, metabolic disorders, oncology, cancer symptoms, neurodegenerative diseases, diseases of the central nervous system, peripheral neuropathy, neurogenic symptoms, Hypoxic-ischemic encephalopathy, stroke, motion sickness, chemically induced sickness, diabetes, obesity, obesity associated with diabetes, bulimia, psychiatric disorders, schizophrenia, and drug, alcohol and nicotine abuse; sanitary preparations for medical purposes; pure extracts of medicinal plants and herbs for medical, veterinary and pharmaceutical purposes; foodstuffs for medicinal purposes, namely, medicated supplements for foodstuffs for babies and animals; herb teas for medicinal purposes; all of the foregoing containing cannabidiolACTIVE—
009Computer programmes for collection, editing, organizing, modifying, managing, transmission, storage and sharing of data and information for use in relation to clinical trials, educational matters and pharmaceutical preparations and substances; computer software for collection, editing, organizing, modifying, managing, transmission, storage and sharing of data and information for use in relation to clinical trials, educational matters and pharmaceutical preparations and substances; data processing apparatus; pre-recorded optical discs featuring information and promotional materials relating to clinical trials, educational and pharmaceutical preparations and substances; information stored on electronic, magnetic and/or by optical means, namely, audio and video recordings featuring information and promotional materials relating to clinical trials, educational and pharmaceutical preparations and substances; downloadable electronic publications in the nature of books, periodicals, journals, magazines, newsletters and reports featuring information and promotional materials relating to clinical trials, educational and pharmaceutical preparations and substances; electronic teaching publications in the nature of books, periodicals, journals, magazines, newsletters and reports featuring information and promotional materials relating to clinical trials, educational and pharmaceutical preparations and substancesACTIVE—
010Surgical, medical, dental and veterinary apparatus, instruments and implements, namely, drug delivery systems; applicators for pharmaceutical preparations, namely, drug delivery systems; drug inhalation devices, namely, inhalers and nebulizers for medical purposes; apparatus for drug administration, namely, drug delivery systems; drug delivery devices, namely, medical syringes, and transdermal patches sold without medication; structural parts and fittings for all of the aforesaid goodsACTIVE—
016Paper; printed matter, namely, books, periodicals, journals, magazines, newsletters and reports featuring information and promotional materials relating to clinical trials, educational matter and pharmaceutical preparations and substances; packing materials of paper or cardboard; wrapping paper; packaging boxes of paper, paperboard or cardboard; stationery; photographs; printed instructional and teaching material in the field of clinical trials, educational and pharmaceutical preparations and substances; printed teaching and instructional material for research on health, drugs, pharmaceuticals, medical and technical laboratory mattersACTIVE—
031Agricultural seeds; flowers; live plantsACTIVE—
041Educational services, namely, classes, seminars and workshops in the fields of clinical trials, educational matters and pharmaceutical preparations and substances; tuition training services in the field of clinical trials; provision of training and instruction services in the field of clinical trials, educational and pharmaceutical preparations and substances; publication of books and texts; publishing of electronic publications provision of online electronic publications in the nature of books, periodicals, journals, magazines, newsletters and reports featuring information and promotional materials relating to clinical trials, educational matter and pharmaceutical preparations and substances; arranging and conducting symposiums, conferences, congresses and exhibitions for educational purposes in the field of clinical trials, educational matter and pharmaceutical preparations and substances; advisory, information and consultancy services relating to all of the aforesaidACTIVE—
042Scientific and technological services, namely, scientific and technological research services relating to clinical trials and pharmaceutical preparations and substances; scientific research services; design services in the field of clinical trials and pharmaceutical preparations and substances; industrial design services; computer programming services; technical and scientific consultancy and research services in the field of clinical trials and pharmaceutical preparations and substances; testing and analysis of pharmaceutical preparations and substances; computerised analysis of scientific data; scientific laboratory services in the field of clinical trials and pharmaceutical preparations and substances; industrial analysis and research services in the field of clinical trials and pharmaceutical preparations and substances; medical research relating to epilepsy; analysis of medical research relating to epilepsy; chemical analysis services; chemical, biological, biotechnology and biomedical research services; research and development services in the field of clinical trials and pharmaceutical preparations and substances; conducting clinical trials for others; clinical research, namely, scientific research; providing medical research clinical trial information via a website; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; advisory, information and consultancy services relating to all of the aforesaidACTIVE—
044Medical services; healthcare services; veterinary services; medical analysis services, namely, medical consultations; horticultural services; provision of pharmaceutical information, namely, providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals via the internet; providing medical information on the internet; advisory, information and consultancy services relating to all of the aforesaidACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
May 23, 2016MAB6ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
May 23, 2016ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Oct 20, 2015NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Aug 25, 2015NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Aug 25, 2015PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 5, 2015NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jul 17, 2015PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Jul 16, 2015CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 13, 2015XAECEXAMINER'S AMENDMENT ENTERED—
Jul 13, 2015GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jul 13, 2015GNEAEXAMINERS AMENDMENT E-MAILED—
Jul 13, 2015CNEAEXAMINERS AMENDMENT -WRITTEN—
Jun 22, 2015XAECEXAMINER'S AMENDMENT ENTERED—
Jun 18, 2015GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jun 18, 2015GNEAEXAMINERS AMENDMENT E-MAILED—
Jun 18, 2015CNEAEXAMINERS AMENDMENT -WRITTEN—
Apr 20, 2015GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Apr 20, 2015GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Apr 20, 2015CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Mar 19, 2015TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Mar 19, 2015CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Mar 19, 2015ALIEASSIGNED TO LIE—
Mar 11, 2015TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 11, 2014GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 11, 2014GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 11, 2014CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 8, 2014DOCKASSIGNED TO EXAMINER—
Aug 27, 2014MPMKNOTICE OF PSEUDO MARK E-MAILED—
Aug 26, 2014NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 18, 2014NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance